Topic:
M&A
Latest Headlines
Latest Headlines
Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma
Elan's ($ELN) board of directors has rebuffed the most recent acquisition offer from Royalty Pharma, saying that the bid valued at $6.4 billion undervalues the Ireland-based biopharma group and robs investors of the best value for their shares. With its eyes on Elan's prized Tysabri royalty stream, Royalty made the most recent $12.50-per-share offer on Monday.
Nordion sells off drug unit for $200M, focuses on contracting
Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Novo nabs anti-infectives outfit in $700M buyout
Turns out there was some truth behind the rumors that 3i was shopping the anti-infectives company Xellia.
Novo A/S snatches up antibacterials-maker Xellia as part of new investment strategy
Novo A/S, the Danish holding company of and major shareholder in Novo Nordisk, said today it is pursuing a new piece of its investment strategy focused on more well-established companies as it announced the $700 million purchase of anti-infectives maker Xellia Pharmaceuticals.
Warner Chilcott CEO up for $9.2M handshake after Actavis deal
As the dust settles around Actavis' announced buyout of Warner Chilcott, it's time to dig into some of the nitty-gritty details about "New Actavis." For instance, which of Warner's top people will stick around--and if they don't, how much severance might they collect on the way out? And just how big is the tax cut Actavis expects from making the deal?
Shire eyes takeover protection as bid rumors swirl, Mail says
Shire ($SHPG) is a perennial entry on everybody's favorite M&A target list. Now, according to the Daily Mail , Shire is putting its ducks in a row for a potential "special dividend" to counter any takeover interest. Word is, an £11 billion hostile bid is coming.
Actavis nabs Warner Chilcott in a $8.5B stock swap
Actavis and Warner Chilcott have struck a deal. And it's bigger than the $5 billion-or-so that was bandied about while the companies negotiated. About $3 billion bigger, in fact: According to Actavis, the company will acquire Warner in a stock swap worth $8.5 billion.
Elan orchestrates $693M biotech buyout, $90M spinout in deal frenzy
In a dealmaking frenzy, cash-rich Elan has agreed to pay up to $693 million for a biotech company focused on rare diseases, picked up a big share of a start-up specialty pharma company based in Dubai, spun out its sole remaining clinical asset into a new company with $90 million in financing and set up an $800 million debt offering to help keep the deals coming.
Quest buys Humana's lab business, inks testing deal
Quest Diagnostics is on a buying spree to grow its testing business, and now the company has signed a deal to buy the toxicology and clinical laboratory segment of health insurance giant Humana.
WSJ: Novartis said to eye $16B offer for Actavis
Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
